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converted into absolute value, as oppose to a gradual rise in the number of Mon2/ml,
the number of mDC2/ml remain gradually decreased with the progress of plaque
vulnerability. Plasma levels of Lp-PLA2, PTX3, FABP4 and myeloperoxidase, all of
which reﬂected coronary plaque vulnerability, were positively correlated with the
number of Mon2/ml, but negatively with the number of mDC2/ml.
Conclusions: Circulating subsets of mDC2 and Mon2 appear to be promosing
markers of plaque stabilization and rupture.
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Relationship between Stress Hyperglycemia and in hospital Mortality and
Complications in Patients with Acute Myocardial Infarction
Zhou Na, Li Zhen
First Afﬁliate Hospital Of Dalian University
Objectives: To investigate the effect of stress hyperglycemia on the mortality and
cardiovascular events in patients with acute myocardial infarction (AMI).
Methods: The study covered 1226 patients with the diagnosis of acute myocardial
Infarction admitted in CCU from January 2010 to December 2012 in the First
Afﬁliate Hospital of Dalian University. Based on the level of fasting blood glucose
(FBG), all patients were grouped into two groups: high blood glucose group (HBG
group, 7mmol/L) and non-high blood glucose group (non-HBG group, <7mmol/L).
Based on the history of diabetes were grouped into non-diabetes mellitus group
(NDM group) and diabetes mellitus group (DM group). According to the level of
FBG, patients within DM and NDM group were further divided into groupA
(FBG<7.0mmol/L), groupB (7.0mmol/LFBG<9.0mmol/L), groupC (9.0mmol/
LFBG<11.1mmol/L),groupD (FBG11.1mmol/L), respectively. Compare the dif-
ferences of the mortality and the rate of acute heart failure, cardiogenic shock and
main arrhythmias among these groups.
Results: The rate of high FBG is 34.1% in all AMI, among 37% patients without
history of diabetes mellitus. Compare with the 808 non-HBG groups patients, the 418
HBG group patients had higher mortality (9.1% vs 2.1%) and higher rate of acute
heart failure (37.8% vs 21.2%), cardiogenic shock (7.9% vs 0.7%) and main ar-
rhythmias (25.6% vs 16.5%) (all P<0.01). The mortality (6.4% vs 3.7%) and the rate
of acute heart failure (35.9% vs 23%) and cardiogenic shock (6.6% vs 1.7%) are
greater in the 362 DM group patients than the 864 NDM group (P<0.05).Among the
NDM group, the mortality and cardiovascular complications increased incrementally
with the increasing of FBG. Compared with groupA, the mortality and the rate of
acute heart failure, cardiogenic shock and main arrhythmias of groupB, groupC,
groupD are signiﬁcantly higher (all P<0.05). Compared with groupB, that mortality of
groupD increase obviously (30% vs 2.0%, P<0.01). In the DM group, the mortality
showed no signiﬁcant differences with the increased FBG levels, but the rate of acute
heart failure increased incrementally as FBG reached 9 mmol/L compared with group
A (P<0.01). The mortality of impaired fasting glucose (IFG) patients is similar to the
patients with normal FBG (2.4% vs 1.9%,P>0.05), and signiﬁcantly lower than the
patients with FBG7.0mmol/L (11.5% vs 2.4%,P<0.01).
Conclusions: The stress hyperglycemia could be used as a predictor of inhospital
mortality and cardiovascular events for patients with AMI. The elevation of FBG
increases the mortality and the incidence of acute heart failure, cardiogenic shock, and
main arrhythmias of patients with AMI. But the effects were not consistent between
DM and NDM patients. In NDM patients, as the FBG level increased, the mortality
increased signiﬁcantly, but this results was not obtained in DM group. In DM group,
the incidence of acute heart failure was signiﬁcantly increased as the FBG level
increased.
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The changes of PPARg and EPCs in patients with ACS complicated with
diabetes mellitus and the effect of Irbesartan on them
Li Xiaoyan, Sun Qing
Department of Cardiology, General Hospital of Jinan Military Region
Objectives: To observe the level of PPARg and EPCs in patients suffered from ACS
combined with Type-2 diabetes mellitus (T2DM) and ACS without T2DM, analysis
the relationship between PPARg, EPCs and ACS, T2DM, furthermore explore the
inﬂuence of Irbesartan on them to study the mechanisms of endothelial protection
beyond the antihypertensive effect of Irbesartan, hoping to ﬁnd a new treatment
method for ACS combined with T2DM.
Methods: 102 patients suffered from ACS was enrolled into our study, of which 52 of
them combined with T2DM (ACSDM group) and the other 50 patients only suffered
from ACS. Meanwhile, we selected 30 patients without coronary heat disease and
T2DM as the control group. To all patients, blood was drew when they were enrolled
to detect the level of PPARg and CD34+/CD309+ EPCs. All basic clinic data, CAG
and then Gensini score were compared among all groups. ACSDM group patients
were divided into A, B two group randomly. Patients, who were in A group, were
treated with Irbesartan 75mg po qd excepting conventional treatment of coronary heart
and diabetes. Patients, who wre in B group, were treated without Irbesartan. Blood
was drew again after 12 weeks. The level of PPARg was detected by enzyme-linked
immunosorbent method, meanwhile EPCs was detected by Flow cytometry instru-
ment. We analyed datas of each group by applicating of SPSS17.0.
Results: (1) The basic clinic data among each group, such as age, sex, body mass
index (BMI), smoking history, blood pressure, stain use, TG, HDL-CH, TC, LDL-CH,
blood urea nitrogen, creatinine were no difference (P all>0.05). CHD history, STEMI/
NSTEMI were no difference in ACS group and ACSDM group (P all>0.05). FPG,C126 JACC Vol 64/16/Suppl C j October 16–1HbA1c in the ACSDM group were signiﬁcantly much more than those in the ACS
group and control group (P <0.05). (2) The levels of PPARg of ACS group and
ACSDM group, when compared with control group (295.5625.06 ng/L), were
decreased signiﬁcantly (P all <0.05), and the ACSDM group was much lower than the
ACS group (P<0.05). (3) EPCs levels in ACS and ACSDM group were also
signiﬁcantly lower, when compared with control group (0.05840.0142%, and the
ACSDM group was much lower than the ACS group (P<0.05). 4 Gensini points in
ACSDM group was much higher than that of the ACS group (42.2425.46 VS.
30.2618.35, P<0.01). 5 Levels of PPARg and EPCs were signiﬁcatly correlated
positively (r¼0.658, P<0.01). Gensini scores of patients with ACS was correlated
negatively with both level of PPARg (r¼-0.484,P<0.05), and EPCs (r¼-
0.435,P<0.05). Levels of PPARg and EPCs in combined group were signiﬁcantly
correlated positively (r¼0.558, P<0.01). 6 After 12 weeks intervention of irbesartan,
the level of PPARg of A group increased signiﬁcantly compared with pre-treatment
levels [(226.1725.95) ng/L VS. (234.5526.20) ng/L, P<0.01], so did the level of
EPCs [(0.02840.0111) % VS. (0.03110.0102) %, P<0.01]. There was a signiﬁcant
positive relationship between them (r¼0.767, P<0.01). The level of PPARg and EPCs
of B group had on statistical difference after 12 weeks conventional treatment
(P all>0.05).
Conclusions: The level of PPARg, EPCs of patients with ACS are siganiﬁcantly
lower than those of control group, being much lower in ACSDM group. PPAR g and
EPCs level both decrease with the increasing of the degree of coronary artery stenosi.
Irbesartan, can improve the levels of PPARg and EPCs in patients with ACS and
T2DM, which probably become a new targets for therapeuty.
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Bleeding outcomes in low-mediate risk acute coronary syndrome patients
receiving stenting predicted by adenosine diphophate induced platelet
aggregation after initiation of clopidogrel: 6 months follow-up
Cui Tongtao, Huimin Yu, Taiming Dong, Bin Zhang, Hong Yan, Handong Wu,
Hongtao Liao, Lijun Jin
Department of Cardiology, Guangdong General Hospital, Guangdong Academy of
Medical Sciences, Guangdong Cardiovascular Institute
Objectives: The correlation of enhanced platelet responder to clopidogrel with
bleeding outcome and entry-site complication has rarely been characterized in China
population undergoing percutaneous coronary intervention (PCI). The aim of present
study is to access the prognostic signiﬁcance of optimal platelet inhibition according
to a given clinical state and ethnicity.
Methods: A total of 278 non high risk acute coronary syndrome (ACS) patients
indicated for PCI were enrolled.Adenosine diphophate induced maximal platelet
aggregation (ADP-PG max) was assessed with Lumi-Aggregometer by light trans-
mission aggregometry method. The primary endpoint was the incidence of Throm-
bolysis in Myocardial Infarction (TIMI) deﬁned bleeding outcome and signiﬁcant
entry-site complication within hospital and 6 months follow-up period. Blood was
obtained for platelet aggregation 24h after PCI and 1 month follow up respectively.
Receiver-operating characteristic (ROC) curve analysis was conducted to reveal the
optimal platelet aggregation value deﬁning enhanced clopidogrel responder for as-
sociation of measurements with endpoints.
Results: A total of 24 patients (8.6%) met with primary endpoint in the study, while 4
(1.4%) TIMI major bleeding events, 11 (4.0%) minor bleeding events and 9 (3.2%)
signiﬁcant entry-site complications were observed. Follow-up ADP-PG max
(OR¼0.96, 95%CI, 0.93-0.99; p¼0.008) and renal insufﬁciency (OR¼3.38 95%CI,
1.26-9.19; p¼0.02) were associate with the prediction of bleeding events. The optimal
cutoff for follow up ADP-PG max was 24.5% [area under the curve 0.72 (95%
conﬁdence interval 0.59-0.85), p<0.001]. Bleeding occurred in 26.2% of patients with
clopidogrel enhanced response (16/61), as compared with 3.7% of remaining patients
(8/217), (hazard radio, 9.26; p<0.001).
Conclusions: In conclusion, enhanced clopidogrel responsiveness was associated with
a higher risk of bleeding and entry-site complication. Platelet function test detected at
an appropriate sampling time after clopidogrel administration may help identify high
bleeding risk patients after coronary intervention.
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Discrepancy in Measuring On-Clopidogrel Platelet Responsiveness by
Vasodilator-Stimulated Phosphoprotein Phosphorylation and Platelet
Aggregation Is Associated with Smoking Status Following ST-Elevation
Myocardial Infarction
Zhou Xin, Jing Sun, Guo-Hong Yang, Wen-Jie Ji, Rui-Yi Lu, Xin-Lin Liu,
Zhao-Zeng Guo, Ji-Hong Zhao, Tie-Min Jiang, Yu-Ming Li
Tianjin Key Laboratory of Cardiovascular Remodeling and Target Organ Injury,
Institute of Cardiovascular Disease and Heart Center, Pingjin Hospital
Objectives: To investigate the potential mechanism accounting for the discrepancy of
VASP phosphorylation and platelet aggregation (PAG) in evaluating high on-clopi-
dogrel platelet reactivity in patients following ST segment-elevation myocardial
infarction (STEMI).
Methods: 90 consecutive STEMI patients scheduled for emergency percutaneous
coronary intervention (PCI) were enrolled. Platelet reactivity after clopidogrel loading
dose (300 mg) was determined by two methods [platelet reactivity index (PRI),
measured by vasodilator-stimulated phosphoprotein (VASP) phosphorylation ﬂow9, 2014 j GW-ICC Abstracts/Cardiovascular Disease Clinical Research
cytometry and ADP-induced platelet aggregation (PAG), measured by light trans-
mission aggregometry].
Results: All the subjects were dichotomized according to PRI medians (normal-re-
sponders: PRI<41.85%, n¼45 and low-responders: PRI>41.85%, n¼45) and PAG
medians (normal-responders: PAG<65.5%, n¼49 and low-responders: PAG>65.5%,
n¼41). No signiﬁcant differences of demographic data were found between normal-
and low-responders determined by the two methods. To further explore the potential
clinical characteristics associated with the discrepancy of VASP phosphorylation and
PAG in evaluating platelet reactivity, patients who were normal-responders to both
methods, or who were low-responders to both methods, were deﬁned as “concor-
dance” group (n¼60). Otherwise, the rest patients were deﬁned as “discrepancy
group” (n¼30). Stepwise binary logistic regression analysis revealed that among
factors that potentially inﬂuence the consistency of the two methods, smoking was the
only independent predictor associated with the discrepancy of the two methods (OR
3.333, 95% CI 1.120 to 9.917, P¼0.030). After adjusted by the traditional factors
(age, gender, hypertension and diabetes) that may inﬂuence the responsiveness of
platelets to clopidogrel, smoking remains statistically predict the discrepancy between
these two methods in evaluating platelet reactivity (OR 4.399, 95% CI 1.105 to
17.522, P¼0.036).
Conclusions: The present study shows that smoking is an independent factor that
inﬂuences the consistancy of VASP phosphorylation and ADP-induced PAG in
evaluating high on-clopidogrel platelet reactivity in patients with STEMI.
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The platelet receptor P2Y12 gene polymorphisms and thrombelastography could
predict the risk of bleeding events in clopidogrel-treated Chinese patients after
percutaneous coronary intervention
Zhang Jiahui, Tang Xiaofang, Wang Jing, Yao Yi, Gao Runlin, Gao Zhan, Wu Yuan,
Chen Jue, Meng Xianmin, Yuan Jinqing
Fu Wai Hospital, Cardiology, Beijing, China
Objectives: Polymorphisms in the platelet receptor P2Y12 gene have been suggested
to inﬂuence the pharmacodynamics of clopidogrel and prognosis of patients treated
with clopidogrel. The effect of P2Y12 polymorphisms and the prognostic utility of
thrombelastography (TEG) on bleeding events of clopidogrel treatment have not yet
been reported in Chinese patients after percutaneous coronary intervention (PCI). This
study sought to investigate the impact of P2Y12 polymorphisms and the predictive
value of TEG on the risk of bleeding in clopidogrel-treated Chinese patients after PCI.
Methods: Between January 2011 and June 2012, 504 consecutive patients with acute
coronary syndromes (ACS) who received coronary angiography or an uneventful PCI
and were exposed to clopidogrel treatment for 12 months, were enrolled in the single-
center registry. 18 tag single nucleotide polymorphisms (SNPs) selected from P2Y12
gene and the gain of function CYP2C19*17 allele were detected by the ligase
detection reaction. The antiplatelet effect of clopidogrel was assessed by TEG. The
primary clinical safety end point was the incidence of major bleeding deﬁned ac-
cording to the Bleeding Academic Research Consortium (BARC) criteria, including
type 3 and 5 in the analysis. The primary clinical efﬁcacy end point was a composite
of cardiovascular death, non-fatal myocardial infarction, unplanned target vessel
revascularization, and stent thrombosis. The follow-up period was 12 months.
Results: Major bleeding events occurred in 47 patients (9.3%) according to BARC
criteria, including 12 patients or 2.4% with BARC type 3b bleeding, 35 patients or
6.9% with BARC type 3a bleeding. By receiver operating characteristic curve anal-
ysis, the TEG results of ADP inhibition >80.7% had a predictive value of BARC type
3 bleeding with an area under the curve¼ 0.556 (95%CI 0.511-0.6, p¼0.045).
Binary logistic regression analysis identiﬁed ADP inhibition >80.7% (OR: 2.637,
95%CI: 1.268-5.483, p¼0.009), and two tag SNPs rs6785930 (OR: 2.305, 95%CI:
1.180-4.503, p¼0.015), rs6809699 (OR: 3.227, 95%CI: 1.587-6.558, p¼0.001)) as
signiﬁcant independent predictors of BARC type 3 bleeding in the context of gain of
function CYP2C19*17 allele. A total of 34 ischemic events occurred. However, no
signiﬁcant inﬂuence of tag SNPs of P2Y12 on the occurrence of ischemic events was
found. TEG did not predict ischemic events, either.
Conclusions: In our study population, the P2Y12 genetic locus harbors SNPs that
could have inﬂuence on bleeding events after PCI, and the ADP inhibition of TEG had
a predictive value of bleedings.
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CORRELATION OF NLRP3 WITH PROGNOSIS IN ACUTE CORONARY
SYNDROME
Qu Peng
Department of Cardiology, Second Afﬁliated Hospital of Dalian Medical University,
Dalian, Liaoning, China
Objectives: To assess whether NLRP3 concentration was related to atherosclerotic
severity and any speciﬁc features of coronary lesions on angiographic assessment and
if NLRP3 concentration has any prognostic value in acute coronary syndrome (ACS)
patients.
Methods: In our study we examined one hundred and twenty three (123) subjects
including 30 controls (C¼30) and 93 Acute coronary Syndrome (ACS¼93) patients.
We evaluated the association of baseline NLRP3 level with clinical presentation,
angiographic characteristics, SYNTAX score, Clinical SYNTAX score (CSS) and
Gensini score. Follow up for major adverse cardiac events (MACE) was carried out atJACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/C6 months and Kaplan-Meier curves were constructed. Prognostic values of NLRP3,
GRACE score and TIMI score were determined by receiver operating characteristic
(ROC) curves.
Results: NLRP3 was found to be elevated in ACS patients (P<0.05). There was
positive correlation between NLRP3 and SYNTAX score, Clinical SYNTAX score
and Gensini score. P value was found to be 0.01 in all cases. NLRP3 was also
associated with severity of coronary disease based on number of vessels (P<0.05)
involved and the number of lesions (P<0.05) present and also on the presence or
absence of bifurcation lesions (P¼0.05). The 6 months mortality was 1.07% (1 pa-
tient), myocardial infarction 2.15% (2 patients) and unstable angina 3.22% (3 pa-
tients), target vessel revascularization was 3.22% (3 patients) and cardiac failure was
4.3% (4 patients). Receiver operating characteristic (ROC) curves of NLRP3 showed
good predictive value for MACE.
Conclusions: There are no previous studies related to correlation of NLRP3 levels and
severity of atherosclerosis. Our study showed positive correlation between NLRP3
concentration and SYNTAX score, CLINICAL SYNTAX score, GENSINI score,
Grace Score and TIMI score. Further studies are required to test the utilization of
NLRP3 in risk assessment and in selecting appropriate therapies for patients in low
and high risk groups as well as its utilization in decision making regarding the choice
of revascularization therapy.
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Effect of different dose of rosuvastatin on the levels of serum adiponectin, vWF
and endothelial function in patients with acute coronary syndrome
Zhang Zhu-Lin, Zhang Li-Zhen, Ma Xiu-Rui, Lan Wen-Yan
Shanxi Cardiovascular Hospital
Objectives: To observe and compare the effect of different dose of rosuvastatin on the
levels of serum adiponectin (APN), von Willebrand factor (vWF) and endothelial
function in patients with acute coronary syndrome (ACS).
Methods: 120 patients with acute coronary syndrome were randomly assigned to
receive 10 mg/day or 20 mg /day of rosuvastatin. The levels of serum lipids, adipo-
nectin (APN), von Willebrand factor (vWF) and dilation of the brachial artery were
assessed before the therapy, 4 weeks and 8 weeks after the therapy.
Results: All the levels of total cholesterol, low-density lipoprotein cholesterol,
triglycerides were signiﬁcantly decreased from baseline values in Rosuvastatin
10 mg/d and 20 mg/d groups, and the levels of high-density lipoprotein cholesterol
increased. After treatment, the level of APN was increased, brachial artery ﬂow-
mediated endothelium-depended dilation were improved; while the level of vWF was
decreased. These effects were more signiﬁcant with rosuvastatin for 8 weeks than
4 weeks; but there was no difference between 10 mg/d and 20 mg/d.
Conclusions: Treatment with rosuvastatin 10 mg/d and 20 mg/d could improve
abnormal serum lipids and endothelial function, increase APN, decrease vWF. The
effect was greater with rosuvastatin for 20 mg/d than 10 mg/d and 8 weeks than
4 weeks.
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Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the
pharmacokinetics and pharmacodynamics response to clopidogrel in patients
with acute coronary syndrome in the Chinese Han population
Wang Xiaqin1,2, Wang Bangnin1
1the First Afﬁliated Hospital, Anhui Medical University, 2the Fourth Afﬁliated
Hospital, Anhui Medical University
Objectives: Clopidogrel is an inhibitor of platelet ADP P2Y12 receptors and plays
an important role in the prevention of stent thrombosis. Despite certain clinical
beneﬁt using this drug in patients undergoing percutaneous coronary intervention
(PCI), some patients do not attain adequate antiplatelet effects. Several studies report
that the genetic variation in CYP2C19 and ABCB1 is associated with an impaired
response to clopidogrel. This study was designed to investigate the genetic variants
of ABCB1, CYP2C9*2, CYP2C19*3, CYP3A4, CYP3A5, P2RY12 and P2Y1 on
exposure to clopidogrel (CLP), its active (clopi-H4) and inactive (CLPM) metabo-
lite, and platelet response to clopidogrel in Chinese Han population with acute
coronary syndrome.
Methods: The degree of inhibition of platelets was assessed using the light trans-
mittance aggregometry (LTA). Plasma concentrations of CLP, clopi-H4 and CLPM
were measured by HPLC-MS-MS method in 401 consecutive patients. Patients were
either on 75 mg clopidogrel-maintenance dose or received a 300 mg clopidogrel-
loading dose.
Results: In both the treatment groups, carriage of CYP2C19*2 and ABCB1 C3435T
was associated with lower exposure to clopi-H4 (P< 0.05) and thus decreased platelet
inhibition (P< 0.05), There was no signiﬁcant association between variant allele
PON1 and clopi-H4 formation or antiplatelet response to clopi-H4 in both groups (P>
0.05). CYP2C19*2 is a determinant for the formation of the active metabolite of
clopidogrel and its antiplatelet effects. Meanwhile, ABCB1 C3435T also plays an
important role in intestinal absorption of clopidogrel, which will further affect the
exposure to clopi-H4.
Conclusions: In both the treatment groups, carriage of CYP2C19*2 and ABCB1
C3435T was associated with lower exposure to clopi-H4 (P< 0.05) and thus decreased
platelet inhibition (P< 0.05), There was no signiﬁcant association between variant
allele PON1 and clopi-H4 formation or antiplatelet response to clopi-H4 in both
groups (P> 0.05). CYP2C19*2 is a determinant for the formation of the activeardiovascular Disease Clinical Research C127
